Triple
T14008622
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Sinovac |
E337018
|
entity |
| Predicate | notableVaccine |
P22
|
FINISHED |
| Object | CoronaVac |
E1074414
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CoronaVac | Statement: [Sinovac, notableVaccine, CoronaVac]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CoronaVac Context triple: [Sinovac, notableVaccine, CoronaVac]
-
A.
CoronaVac
chosen
CoronaVac is an inactivated-virus COVID-19 vaccine developed by the Chinese biopharmaceutical company Sinovac Biotech and widely used in global vaccination campaigns.
-
B.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
C.
Sputnik V COVID-19 vaccine
Sputnik V COVID-19 vaccine is a Russian-developed viral vector vaccine against COVID-19 that gained global attention as one of the first vaccines authorized for use during the pandemic.
-
D.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
E.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: notableVaccine Context triple: [Sinovac, notableVaccine, CoronaVac]
-
A.
notableSafety
Indicates that an entity is recognized for having significant safety characteristics, performance, or impact relative to others.
-
B.
notableFor
chosen
Indicates that an entity is especially recognized or distinguished for a particular quality, achievement, characteristic, or role.
-
C.
notableExposure
Indicates that an entity has received significant public attention, visibility, or coverage, making it notably exposed or recognized.
-
D.
notableDuring
Indicates that something was especially prominent, active, or significant during a particular time period or event.
-
E.
notableRelease
Indicates that an entity is a significant or prominent release (such as a major version, edition, or launch) associated with another entity.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d81c645c5c8190b1fd16a285a1b78a |
completed | April 9, 2026, 9:38 p.m. |
| NER | Named-entity recognition | batch_69de2ed44f90819099ad08c09c066b56 |
completed | April 14, 2026, 12:11 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69fbc329891c8190b4dcb9913e235a1c |
completed | May 6, 2026, 10:39 p.m. |
| PD | Predicate disambiguation | batch_69dd465dfbc4819090d8c61fd572d35f |
completed | April 13, 2026, 7:39 p.m. |
Created at: April 9, 2026, 10:19 p.m.